Results: 197

Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study

Clinics; 76 (), 2021
OBJECTIVES: Despite higher rates of sustained virologic response (SVR), important concerns remain when patients with decompensated cirrhosis due to hepatitis C virus (HCV) are treated with direct-acting antiviral agents (DAA). Questions include efficacy, safety, and the magnitude of liver function improv...

A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil

Braz. j. infect. dis; 25 (2), 2021
ABSTRACT A retrospective cohort of 11,308 chronic hepatitis C infected patients treated with regimens that included Sofosbuvir (SOF), Daclatasvir (DCV), Simeprevir (SMV), or an association of Ombitasvir, Veruprevir/Ritonavir and Dasabuvir (3D) with or without Ribavirin (RBV) were assessed for sustained v...

Diabetes influences liver stiffness in chronic hepatitis C patients with and without virological cure: A longitudinal study

Clinics; 76 (), 2021
OBJECTIVES: The aim was to prospectively assess the variation in liver stiffness (LS) and the associated factors for LS progression in a cohort of naïve, non-responder (NR), and sustained virological response (SVR) chronic hepatitis C (CHC) patients. METHODS: This was a longitudinal study on CHC patien...

The promising drugs included in WHO's Solidarity Project: a choice based in scientific knowledge and institutional competencies

Mem. Inst. Oswaldo Cruz; 116 (), 2021
BACKGROUND In March 2020, the World Health Organization (WHO) launched the Solidarity Program, probably the largest global initiative to encourage and support research in four promising drugs, named Remdesivir, Hydroxychloroquine, β Interferon and the combination Lopinavir / Ritonavir, to reduce th...

Tratamiento Covid-19
Covid-19 treatment

The main treatment for patients with severe Covid-19 is to maintain adequate ventilatory support and monitor the possible progression of the disease. Therapeutic strategies such as High Flow Nasal Cannula, awake prone position, antithrombotic prophylaxis and the use ...

Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial

Braz. j. med. biol. res; 54 (2), 2021
Influenza viruses exacerbate chronic obstructive pulmonary disease (COPD) with considerable morbidity and mortality. Zanamivir and oseltamivir are effective in treating influenza. However, their efficacy in relieving influenza symptoms in COPD patients remains unknown, with the lack of controlled trials ...

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

J. bras. pneumol; 47 (5), 2021
ABSTRACT Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW. Methods: This was a cross-sectional st...

Risco de Recorrência do Carcinoma Hepatocelular após o Uso de Antivirais de Ação Direta no Tratamento de Hepatite C: Revisão Sistemática e Metanálise

Rev. bras. cancerol; 67 (2), 2021
Introdução: A hepatite C está associada ao desenvolvimento do carcinoma hepatocelular (CHC). O regime terapêutico baseado em interferon vem sendo substituído pelos antivirais de ação direta (AAD) para tratamento da infecção pelo vírus da hepatite C (HCV). Contudo, estudos recen...

Risco de Recorrência do Carcinoma Hepatocelular após o Uso de Antivirais de Ação Direta no Tratamento de Hepatite C: Revisão Sistemática e Metanálise

Rev. bras. cancerol; 67 (2), 2021
Introdução: A hepatite C está associada ao desenvolvimento do carcinoma hepatocelular (CHC). O regime terapêutico baseado em interferon vem sendo substituído pelos antivirais de ação direta (AAD) para tratamento da infecção pelo vírus da hepatite C (HCV). Contudo, estudos recen...

Ongoing living update of potential COVID-19 therapeutics: summary of rapid systematic reviews - 18 December 2020

This is the thirteenth edition of this summary of rapid systematic reviews, which includes the results of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review, 58 therapeutic options are examined....